Report cover image

Europe Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model (Cloud-based, On-premises, and Hybrid Model), By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031

Publisher Knowledge Based Value (KBV) Research
Published Dec 13, 2024
Length 185 Pages
SKU # KBV19421912

Description

Europe Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model (Cloud-based, On-premises, and Hybrid Model), By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031


The Europe Biosimulation Market would witness market growth of 16.3% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Biosimulation Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $644.3 million by 2031. The UK market is exhibiting a CAGR of 15.3% during (2024 - 2031). Additionally, The France market would experience a CAGR of 17.1% during (2024 - 2031).

One of the primary drivers of this market is the rapid advancement in computational power and technologies such as artificial intelligence (AI) and machine learning (ML). These technologies have enhanced the accuracy and scalability of these models, enabling researchers to simulate complex biological interactions that were previously beyond reach.

Initiatives such as the FDA’s Model-Informed Drug Development (MIDD) program have encouraged the adoption of this for regulatory submissions, allowing pharmaceutical companies to expedite approvals and bring innovative therapies to market faster. This regulatory endorsement has also led to integrating this into clinical trial designs, helping researchers identify optimal patient cohorts and minimize risks.

Switzerland and Italy further contribute to the European market, focusing on biotechnology and healthcare digitization. In Switzerland, companies like Novartis and Roche have employed this for cardiovascular drugs and Alzheimer’s treatments, supported by funding from the Swiss Innovation Agency (Innosuisse). Under the National Recovery and Resilience Plan (NRRP), Italy has promoted this for respiratory disorder therapies, with companies like Chiesi Group and academic institutions exploring its potential in rare disease research. These efforts highlight Europe’s collaborative and innovative landscape, where they drives advancements across diverse therapeutic areas.

Based on Product, the market is segmented into Software (Molecular Modeling & Simulation Software, Clinical Trial Design Software, PK/PD Modeling and Simulation Software, Pbpk Modeling and Simulation Software, Toxicity Prediction Software, and Other Software Type) and Services (Contract Services, Consulting, and Other Services Type). Based on Pricing Model, the market is segmented into License-based Model, Subscription-based Model, Service-based Model, and Pay Per Use Model. Based on End Use, the market is segmented into Life Sciences Companies, Academic Research Institutions, and Other End Use. Based on Application, the market is segmented into Drug Discovery & Development, Disease Modeling, and Other Application. Based on Deployment Model, the market is segmented into Cloud-based, On-premises, and Hybrid Model. Based on Therapeutic Area, the market is segmented into Oncology, Cardiovascular Disease, Infectious Disease, Neurological Disorders, and Other Therapeutic Area. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled
  • Certara, Inc.
  • Dassault Systemes SE
  • Advanced Chemistry Development, Inc.
  • Genedata AG (Danaher Corporation)
  • Instem Group of Companies
  • Chemical Computing Group ULC
  • Simulations Plus, Inc.
  • Schrodinger, Inc.
  • PPD, Inc. (Thermo Fisher Scientific, Inc.)
  • Physiomics Plc
Europe Biosimulation Market Report Segmentation

By Product
  • Software
  • Molecular Modeling & Simulation Software
  • Clinical Trial Design Software
  • PK/PD Modeling and Simulation Software
  • Pbpk Modeling and Simulation Software
  • Toxicity Prediction Software
  • Other Software Type
  • Services
  • Contract Services
  • Consulting
  • Other Services Type
By Pricing Model
  • License-based Model
  • Subscription-based Model
  • Service-based Model
  • Pay Per Use Model
By End Use
  • Life Sciences Companies
  • Academic Research Institutions
  • Other End Use
By Application
  • Drug Discovery & Development
  • Disease Modeling
  • Other Application
By Deployment Model
  • Cloud-based
  • On-premises
  • Hybrid Model
By Therapeutic Area
  • Oncology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurological Disorders
  • Other Therapeutic Area
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Table of Contents

185 Pages
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Biosimulation Market, by Product
1.4.2 Europe Biosimulation Market, by Pricing Model
1.4.3 Europe Biosimulation Market, by End Use
1.4.4 Europe Biosimulation Market, by Application
1.4.5 Europe Biosimulation Market, by Deployment Model
1.4.6 Europe Biosimulation Market, by Therapeutic Area
1.4.7 Europe Biosimulation Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
Chapter 4. Competition Analysis – Global
4.1 Market Share Analysis, 2023
4.2 Strategies Deployed in Biosimulation Market
4.3 Porter Five Forces Analysis
Chapter 5. Europe Biosimulation Market by Product
5.1 Europe Software Market by Country
5.2 Europe Biosimulation Market by Software Type
5.2.1 Europe Molecular Modeling & Simulation Software Market by Country
5.2.2 Europe Clinical Trial Design Software Market by Country
5.2.3 Europe PK/PD Modeling and Simulation Software Market by Country
5.2.4 Europe Pbpk Modeling and Simulation Software Market by Country
5.2.5 Europe Toxicity Prediction Software Market by Country
5.2.6 Europe Other Software Type Market by Country
5.3 Europe Services Market by Country
5.4 Europe Biosimulation Market by Services Type
5.4.1 Europe Contract Services Market by Country
5.4.2 Europe Consulting Market by Country
5.4.3 Europe Other Services Type Market by Country
Chapter 6. Europe Biosimulation Market by Pricing Model
6.1 Europe License-based Model Market by Country
6.2 Europe Subscription-based Model Market by Country
6.3 Europe Service-based Model Market by Country
6.4 Europe Pay Per Use Model Market by Country
Chapter 7. Europe Biosimulation Market by End Use
7.1 Europe Life Sciences Companies Market by Country
7.2 Europe Academic Research Institutions Market by Country
7.3 Europe Other End Use Market by Country
Chapter 8. Europe Biosimulation Market by Application
8.1 Europe Drug Discovery & Development Market by Country
8.2 Europe Disease Modeling Market by Country
8.3 Europe Other Application Market by Country
Chapter 9. Europe Biosimulation Market by Deployment Model
9.1 Europe Cloud-based Market by Country
9.2 Europe On-premises Market by Country
9.3 Europe Hybrid Model Market by Country
Chapter 10. Europe Biosimulation Market by Therapeutic Area
10.1 Europe Oncology Market by Country
10.2 Europe Cardiovascular Disease Market by Country
10.3 Europe Infectious Disease Market by Country
10.4 Europe Neurological Disorders Market by Country
10.5 Europe Other Therapeutic Area Market by Country
Chapter 11. Europe Biosimulation Market by Country
11.1 Germany Biosimulation Market
11.1.1 Germany Biosimulation Market by Product
11.1.1.1 Germany Biosimulation Market by Software Type
11.1.1.2 Germany Biosimulation Market by Services Type
11.1.2 Germany Biosimulation Market by Pricing Model
11.1.3 Germany Biosimulation Market by End Use
11.1.4 Germany Biosimulation Market by Application
11.1.5 Germany Biosimulation Market by Deployment Model
11.1.6 Germany Biosimulation Market by Therapeutic Area
11.2 UK Biosimulation Market
11.2.1 UK Biosimulation Market by Product
11.2.1.1 UK Biosimulation Market by Software Type
11.2.1.2 UK Biosimulation Market by Services Type
11.2.2 UK Biosimulation Market by Pricing Model
11.2.3 UK Biosimulation Market by End Use
11.2.4 UK Biosimulation Market by Application
11.2.5 UK Biosimulation Market by Deployment Model
11.2.6 UK Biosimulation Market by Therapeutic Area
11.3 France Biosimulation Market
11.3.1 France Biosimulation Market by Product
11.3.1.1 France Biosimulation Market by Software Type
11.3.1.2 France Biosimulation Market by Services Type
11.3.2 France Biosimulation Market by Pricing Model
11.3.3 France Biosimulation Market by End Use
11.3.4 France Biosimulation Market by Application
11.3.5 France Biosimulation Market by Deployment Model
11.3.6 France Biosimulation Market by Therapeutic Area
11.4 Russia Biosimulation Market
11.4.1 Russia Biosimulation Market by Product
11.4.1.1 Russia Biosimulation Market by Software Type
11.4.1.2 Russia Biosimulation Market by Services Type
11.4.2 Russia Biosimulation Market by Pricing Model
11.4.3 Russia Biosimulation Market by End Use
11.4.4 Russia Biosimulation Market by Application
11.4.5 Russia Biosimulation Market by Deployment Model
11.4.6 Russia Biosimulation Market by Therapeutic Area
11.5 Spain Biosimulation Market
11.5.1 Spain Biosimulation Market by Product
11.5.1.1 Spain Biosimulation Market by Software Type
11.5.1.2 Spain Biosimulation Market by Services Type
11.5.2 Spain Biosimulation Market by Pricing Model
11.5.3 Spain Biosimulation Market by End Use
11.5.4 Spain Biosimulation Market by Application
11.5.5 Spain Biosimulation Market by Deployment Model
11.5.6 Spain Biosimulation Market by Therapeutic Area
11.6 Italy Biosimulation Market
11.6.1 Italy Biosimulation Market by Product
11.6.1.1 Italy Biosimulation Market by Software Type
11.6.1.2 Italy Biosimulation Market by Services Type
11.6.2 Italy Biosimulation Market by Pricing Model
11.6.3 Italy Biosimulation Market by End Use
11.6.4 Italy Biosimulation Market by Application
11.6.5 Italy Biosimulation Market by Deployment Model
11.6.6 Italy Biosimulation Market by Therapeutic Area
11.7 Rest of Europe Biosimulation Market
11.7.1 Rest of Europe Biosimulation Market by Product
11.7.1.1 Rest of Europe Biosimulation Market by Software Type
11.7.1.2 Rest of Europe Biosimulation Market by Services Type
11.7.2 Rest of Europe Biosimulation Market by Pricing Model
11.7.3 Rest of Europe Biosimulation Market by End Use
11.7.4 Rest of Europe Biosimulation Market by Application
11.7.5 Rest of Europe Biosimulation Market by Deployment Model
11.7.6 Rest of Europe Biosimulation Market by Therapeutic Area
Chapter 12. Company Profiles
12.1 Certara, Inc.
12.1.1 Company Overview
12.1.2 Financial Analysis
12.1.3 Regional Analysis
12.1.4 Research & Development Expenses
12.1.5 Recent strategies and developments:
12.1.5.1 Product Launches and Product Expansions:
12.1.5.2 Acquisition and Mergers:
12.1.6 SWOT Analysis
12.2 Dassault Systemes SE
12.2.1 Company Overview
12.2.2 Financial Analysis
12.2.3 Regional Analysis
12.2.4 Research & Development Expense
12.2.5 SWOT Analysis
12.3 Advanced Chemistry Development, Inc.
12.3.1 Company Overview
12.4 Genedata AG (Danaher Corporation)
12.4.1 Company Overview
12.4.2 Financial Analysis
12.4.3 Segmental and Regional Analysis
12.4.4 Research & Development Expense
12.4.5 Recent strategies and developments:
12.4.5.1 Partnerships, Collaborations, and Agreements:
12.5 Instem Group of Companies
12.5.1 Company Overview
12.6 Chemical Computing Group ULC
12.6.1 Company Overview
12.7 Simulations Plus, Inc.
12.7.1 Company Overview
12.7.2 Financial Analysis
12.7.3 Segmental and Regional Analysis
12.7.4 Research & Development Expenses
12.7.5 Recent strategies and developments:
12.7.5.1 Partnerships, Collaborations, and Agreements:
12.7.5.2 Product Launches and Product Expansions:
12.7.5.3 Acquisition and Mergers:
12.7.6 SWOT Analysis
12.8 Schrodinger, Inc.
12.8.1 Company Overview
12.8.2 Financial Analysis
12.8.3 Segmental and Regional Analysis
12.8.4 Research & Development Expenses
12.9 PPD, Inc. (Thermo Fisher Scientific, Inc.)
12.9.1 Company Overview
12.9.2 Financial Analysis
12.9.3 Segmental and Regional Analysis
12.9.4 Research & Development Expenses
12.10. Physiomics Plc
12.10.1 Company Overview
12.10.2 Financial Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us